Yuichiro Ohe
Thoracic oncologist who leads NCC Hospital in Tokyo and has been a Japanese principal investigator on a generation of lung cancer trials.
Yuichiro Ohe has led Japanese participation in EGFR, ALK, and immunotherapy trials in NSCLC and small-cell lung cancer, and directs the National Cancer Center Hospital.
| Title | Journal | Year |
|---|---|---|
| Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA) | NEJM | 2018 |
Pages like this
not linked directly; found by shared links- InstitutionWest Japan Oncology Group
Shares Japanese Society of Medical Oncology, National Cancer Center Hospital, Osimertinib, Small-cell lung cancer.
- PersonJean-Charles Soria
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Non-small-cell lung cancer.
- InstitutionPharmaceuticals and Medical Devices Agency
Shares Japanese Society of Medical Oncology, National Cancer Center Hospital, Osimertinib.
- PersonJohn V. Heymach
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialLAURA
Shares Osimertinib, Non-small-cell lung cancer.
- TrialFLAURA2
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Non-small-cell lung cancer.
- PersonHaruhiko Fukuda
Shares National Cancer Center Hospital, Non-small-cell lung cancer.
- PersonTakashi Kohno
Shares National Cancer Center Hospital, Non-small-cell lung cancer.